ArticleClinicoEconomics and outcomes research : CEOR2026
Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives.
Article in ClinicoEconomics and outcomes research : CEOR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the financial impact of treating CML with later-generation TKIs relative to imatinib on US patients and payers. Methods: The financial impact of later-generation TKIs (asciminib, bosutinib, dasatinib, nilotinib, and ponatinib) and imatinib was measured from patients' and payers' perspectives before (2024) and after the implementation of Inflation Reduction Act (2025), respectively. Changes in patient's annual out-of-pocket (OOP) costs of CML therapies by payer type (Medicare, Medicaid, and commercial) were used to indicate the financial impact on patients. Per patient per year (PPPY) treatment costs were measured as the weighted average cost across indicated adult CML populations derived using FDA label-based dosing and wholesale acquisition costs. Annual OOP limits by payer types were determined through literature review. The financial impact from payers' perspective was estimated as difference in monthly premium based on per member per month (PMPM) budget impact. Results: In 2025, the estimated PPPY cost for imatinib ($22,430 across generic and branded products, weighted by market share) and for later-generation TKIs (all >$100,000 except for dasatinib and nilotinib, which were $72,693 and $89,138, respectively) exceeded annual OOP limits under Medicare Part D, the average commercial plan, and the commercial plan with highest possible annual OOP limit, resulting in no change in patient financial impact when switching from imatinib to a later-generation TKI. An all-payer blended US health plan with 1 million members could expect to have 200 patients with Philadelphia chromosome-positive CML eligible for TKI therapy. Switching from imatinib to a later-generation TKI would increase the PMPM budget impact between $0.76 and $4.23. Conclusion: Both imatinib and later-generation TKI costs were projected to exceed annual OOP caps in 2025, likely resulting in minimal change in insured CML patients' OOP costs. The impact on insurance premiums from the adoption of TKI is likely to be relatively modest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.